Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hydroxypropyl-Î²-cyclodextrin spikes local inflammation that induces Th2 and Tfh responses to the coadministered antigen

ABSTRACT: Gene expression data from mouse organs after hydroxypropyl-Î²-cyclodextrin injection Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. In this study, we reprofiled hydroxypropyl-Î²-cyclodextrin (HP-Î²-CD) as a vaccine adjuvant, and found that it acts as a potent and unique adjuvant. C57BL/6J mice (6 week old, male, n = 3) were injected i.d. or i.p. with a total volume of 200 micro liter of 30% HP-Î²-CD in PBS. The vehicle-control mice (n = 3) were injected with the same volume of PBS. After 6 h, the inguinal LNs, Liver, and Spleen were removed (within one hour for all samples) and global gene expression was obtained by Affymetrix GeneChip.

ORGANISM(S): Mus musculus

SUBMITTER: Yoshinobu Igarashi

PROVIDER: E-GEOD-63332 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 and Tfh responses to the coadministered antigen

Project description:Gene expression data from mouse organs after hydroxypropyl-β-cyclodextrin injection Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. In this study, we reprofiled hydroxypropyl-β-cyclodextrin (HP-β-CD) as a vaccine adjuvant, and found that it acts as a potent and unique adjuvant.

2015-02-15 | GSE63332 | GEO

Cyclodextrin treatment leads to atherosclerosis regression by dissolution of cholesterol crystals and LXR activation

Project description:Atherosclerosis is an inflammatory disease linked to elevated blood cholesterol levels. Since cholesterol retention and cholesterol crystals in arterial walls are key pathogenetic factors for atherogenesis, we assessed the therapeutic potential of increasing cholesterol solubility in vivo. Here we show that treatment of murine atherosclerosis with the cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (CD), a compound that solubilizes lipophilic substances, reduced atherosclerotic plaque size, cholesterol crystal (CC) load and promoted plaque regression even under continuing Western diet. CD solubilized CC and promoted cholesterylester and oxysterol production in macrophages leading to liver X receptor-mediated transcriptional reprogramming with increased cholesterol efflux and decreased inflammation. CD treatment may thus be used to increase cholesterol solubility and clearance to prevent or treat atherosclerosis.

2017-07-01 | GSE47696 | GEO

Cyclodextrin promotes atherosclerosis regression via LXR activation (I)

Project description:Atherosclerosis is an inflammatory disease linked to elevated blood cholesterol levels. Despite ongoing advances in the prevention and treatment of atherosclerosis 1, cardiovascular disease remains the leading cause of death worldwide 2. Continuous retention of apolipoprotein B-containing lipoproteins in the subendothelial space causes a local overabundance of free cholesterol. Since cholesterol accumulation and deposition of cholesterol crystals (CCs) triggers a complex inflammatory response 3 4, we tested the therapeutic potential of increasing cholesterol solubility in experimental atherogenesis. Here we show that treatment of murine atherosclerosis with the cyclic oligosaccharide 2-hydroxypropyl-β-cyclodextrin (CD), a compound that solubilizes lipophilic substances, reduced atherosclerotic plaque size, cholesterol crystal load and promoted plaque regression even under continuing Western diet. CD solubilized CCs and promoted cholesterylester and oxysterol production in macrophages leading to liver X receptor (LXR)-mediated transcriptional reprogramming. CD increased cholesterol efflux from macrophages and substantially augmented reverse cholesterol transport in vivo. Furthermore, CD reduced proinflammatory cytokines in vivo and decreased macrophage responsiveness towards TLR and inflammasome activation. Since CD treatment in humans is safe and CD beneficially affects key pathogenetic factors in atherogenesis it may thus be used clinically to prevent or treat human atherosclerosis .

2016-05-06 | GSE67011 | GEO

Cyclodextrin promotes atherosclerosis regression via LXR activation (II)

2016-05-06 | GSE67013 | GEO

Cyclodextrin-derived Nano-medicine Suppresses the Progression of Colorectal Cancer

Project description:The malignancy of colorectal cancer is connected with inflammation, which poses great therapeutic challenges. To integratetherapeutic targets with anti-inflammation strategy, wedeveloped a biocompatible, non-covalent channel-type nanoparticles that was fabricated through host-guest complexation and multiple assemble of mannose-modified ?-cyclodextrin (M-?-CD) with Regorafenib (RG), denoted as RG@M-?-CD. For in vivo application, the channel-type formulation optimized the pharmacokinetics and bio-distribution of RG. In colitis-associated cancer (CAC) and CT26 models, RG@M-?-CD was proven to be a targeted, safe and effective anti-tumor nanomedicine that suppressed tumor cells proliferation, lesioned neovascularization, and attanuated inflammation. To investigate the therapeutic mechanism of RG@M-?-CD nanomedicine, small pieces of colon tissue with tumors from control group and treatment group were used to perform the microarray for gene expression anaylsis. The RGnanomedicine is constructed through the host-guest assemble between mannose-modified ?-cyclodextrin (M-?-CD) and TKI Regorafenib (RG). With multiple assemble, the host-guest system is transformed into nanoparticle, denoted as RG@M-?-CD (or RG nanomedicine).

2020-09-24 | GSE157993 | GEO

Grapevine cell cultures transcriptomic response to methyl jasmonate and cyclodextrin elicitors

Project description:The specificity and synergisms of methyl jasmonate and cyclodextrin elicitor effects in grapevine were analysed at the transcrptomic level. To this end, 12-14 day old cell cultures established from Vitis vinifera L. cv Monastrell calli were elicited with 50 mM cyclodextrin (CD), 100 µM methyl jasmonate (MJ) or the combination of both elicitros (MJ+CD). The experiment was carried out in triplicate and untreated cell cultures were followed in parallel as a control. Cells of each culture were isolated just prior and 24h after the treatment to obtain RNA. GrapeGen GeneChip microarray hybridization was performed from each sample. ****[PLEXdb(http://www.plexdb.org) has submitted this series at GEO on behalf of the original contributor, Pablo Carbonell-Bejerano. The equivalent experiment is VV44 at PLEXdb.]

2015-11-15 | GSE42312 | GEO

Alteration of lipid homeostasis by hydroxypropyl cyclodextrin improves amiodarone-induced alveolar cell disorder

Project description:Alteration of lipid homeostasis by hydroxypropyl cyclodextrin improves amiodarone-induced alveolar cell disorder

| PRJNA611495 | ENA

Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

Project description:Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

| PRJNA717336 | ENA

Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

Project description:Transcriptome of 2-hydroxypropyl-beta-cyclodextrin treatment in Niemann-Pick disease type C1

| PRJNA717337 | ENA

Transcription profiling time series of human HeLa cells cultivated while sterol depleted from the medium

Project description:The aim of the experiment was to identify novel genes with relevance to cellular cholesterol metabolism. HeLa cells were cultivated while sterol was depleted from the medium by applying 2-Hydroxypropyl-cyclodextrin. RNA for expression profiling was isolated 3h, 4.5h and 6h after depletion.

2008-12-17 | E-TABM-599 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data